PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.

Saved in:
Bibliographic Details
Title: PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.
Authors: Martinez FJ; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France., White M; Infectious Disease Epidemiology and Analytics G5 Unit, Institut Pasteur, Université Paris Cité, Paris, France., Guillotte-Blisnick M; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France., Huon C; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France., Boucharlat A; Chemogenomic and Biological Screening Core Facility, C2RT, Institut Pasteur, Université Paris Cité, CNRS UMR 3523, Paris, France., Agou F; Chemogenomic and Biological Screening Core Facility, C2RT, Institut Pasteur, Université Paris Cité, CNRS UMR 3523, Paris, France., England P; Molecular Biophysics Facility, CNRS UMR 3528, Institut Pasteur, Paris, France., Popovici J; Malaria Reasearch Unit, Institut Pasteur du Cambodge, Pnom Penh, Cambodia., Hou MM; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK., Silk SE; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK., Barrett JR; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK., Nielsen CM; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK., Reimer JM; Novavax AB, Kungsgatan 109, SE-753 18, Uppsala, Sweden., Mukherjee P; Multi-Vaccines Development Program, ICGEB Campus, New Delhi, India., Chauhan VS; International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India., Minassian AM; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Draper SJ; Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK.; NIHR Oxford Biomedical Research Centre, Oxford, UK., Chitnis CE; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France. chetan.chitnis@pasteur.fr.
Source: NPJ vaccines [NPJ Vaccines] 2024 Jan 06; Vol. 9 (1), pp. 10. Date of Electronic Publication: 2024 Jan 06.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature in partnership with the Sealy Center for Vaccine Development Country of Publication: England NLM ID: 101699863 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-0105 (Electronic) Linking ISSN: 20590105 NLM ISO Abbreviation: NPJ Vaccines Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2059-0105
DOI:10.1038/s41541-023-00796-7